TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers found that older adults with faster cognitive decline had fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. Mouse experiments suggest reducing NRF2 in these cells can cause similar changes, but the findings do not show that an existing drug prevents cognitive decline in people.
Researchers have linked dysfunction in oligodendrocytes—brain cells that produce and maintain the insulation around nerve fibers—to faster cognitive decline with age. In a study published in Nature Medicine, analysis of human brain tissue and experiments in mice connected lower activity of the protective protein NRF2 in these cells with abnormal myelin and damage to large nerve fibers, pointing to a possible target for future research.
The research team, led by scientists from the University of Edinburgh and the UK Dementia Research Institute, studied participants in the Lothian Birth Cohort 1936. The cohort has tracked participants’ cognitive abilities from childhood. Between ages 70 and 82, participants completed assessments of memory, information-processing speed and spatial reasoning. Of 1,091 enrolled people, 866 completed additional cognitive testing after age 70.
Nearly all participants experienced some cognitive decline, but the rate differed. In brain tissue examined after participants’ deaths, greater decline was associated with fewer large nerve fibers and abnormal accumulation of myelin, the fatty coating that helps electrical signals travel along nerve fibers. The tissue findings were associated with the pace of decline, not simply with participants’ cognitive scores at one age.
The researchers also found lower levels of NRF2 in oligodendrocytes in people with more severe decline. NRF2 regulates genes involved in cellular protection and function. In mice, reducing NRF2 specifically in oligodendrocytes led to excess myelin, loss of large nerve fibers and less improvement on cognitive tests as the animals aged. The experiments support a possible causal role for the pathway in mice; they do not establish that it causes cognitive decline in people.
A New Target in Aging Brain Research
The results complicate the view that oligodendrocytes are always protective. These cells are essential for maintaining myelin, but the study suggests that when their function changes with age, they may contribute to damage in the nerve fibers they normally support. That possibility could help researchers investigate why cognitive abilities decline at different rates among older adults.
The NRF2 pathway may also offer a lead for treatment research. The source report notes that medicines acting on this pathway are already used for other neurological conditions, including multiple sclerosis. However, that existing use is not evidence that these drugs prevent or treat age-related cognitive decline. Any potential application would need to be tested for safety and benefit in the relevant older population.
NRF2 supplement for cognitive health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The Lothian Birth Cohort gave researchers a long record of cognitive performance, allowing them to compare changes over time with brain tissue collected after death. This design helped distinguish the rate of decline from a person’s score at a single assessment. The human findings are observational: they show an association between cognitive change and tissue features, but cannot by themselves establish which changes came first or what caused them.
The mouse experiments addressed part of that gap by altering NRF2 in oligodendrocytes and examining the resulting effects. The reported similarities between the mice and human tissue strengthen the case for further investigation, but animal results do not establish that the same intervention or mechanism will produce the same outcome in people.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Treatment Evidence Is Still Missing
The findings do not show that reduced NRF2 is the sole cause of cognitive decline, or establish whether changes in oligodendrocytes precede nerve-fiber damage in people. The human tissue analysis identifies associations, while the direct manipulation of NRF2 took place in mice. It is also unclear whether the pathway behaves the same way across different causes of cognitive impairment or across the broader population.
No clinical trial described in the report tested an NRF2-targeting medicine in older adults for age-related cognitive decline. The report does not identify a specific drug, dose or treatment schedule for this purpose, nor does it establish whether changing NRF2 would be safe or effective in that setting.
Testing the NRF2 Pathway in People
The next step is further research to clarify how age-related changes in oligodendrocytes affect myelin and nerve fibers, and whether the NRF2 pathway can be safely targeted to protect cognitive function. Before existing medicines could be considered for this use, researchers would need to test them in appropriately designed clinical studies involving older adults and measure both potential benefits and risks.
For now, the study identifies a biological pathway for follow-up rather than a new treatment. The report does not specify a clinical trial or a timeline for testing NRF2-targeting drugs against age-related cognitive decline.
Key Questions
What brain cells did the study examine?
It focused on oligodendrocytes, cells that produce and maintain myelin, the coating around nerve fibers.
What was associated with faster cognitive decline?
In the human tissue examined, greater decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes.
Does the research prove that NRF2 changes cause cognitive decline in people?
No. The human findings are associations. Experiments reducing NRF2 in oligodendrocytes produced related changes in mice, but that does not prove the same causal effect in people.
No such treatment is established by the study. Medicines that act on NRF2 are used for other conditions, but their safety and effectiveness for age-related cognitive decline have not been demonstrated here.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
